Sale of ICX-TRC
18th March 2010
Regenerative Medicine Assets Limited (formerly
Intercytex Group plc) today announces that it has completed the
sale of certain assets related to its hair regeneration product
ICX-TRC from its wholly owned subsidiary Intercytex Limited to
Aderans Research Institute Inc. (an affiliate of Aderans Co Ltd of
Japan, and Bosley) for US$200,000.
The Company continues with detailed discussions regarding the
sale of its remaining business assets, primarily Vavelta, and
anticipates making further announcements in due course.
Enquiries
For more information, contact:
| Intercytex Group
plc |
|
| Nick Higgins, Director |
Tel: 0161 904 4500 |
| Max Herrmann, Director |
|
| |
|
| Aderans Research |
|
| Vern Liebmann, Vice President
Operations |
Tel:
+1.678.213.1913 |
Notes for Editors
ICX-TRC is an autologous hair regeneration therapy, a suspension
of human dermal papilla (DP) cells, for the treatment of male
pattern baldness and female diffuse alopecia. DP cells stimulate
the generation of new hairs when injected into the scalp in close
proximity to the epithelial cells which generate new hair. It is
intended that ICX-TRC will be used by specialists in hair
transplant centres, dermatologists and plastic surgeons to treat
patients with hair thinning or hair loss. ICX-TRC completed a Phase
II trial in March 2009.
|
Contact Us
